PMC9459224_01
(A-D) The enhanced computed tomography (enhanced-CT) scans of the tumor before neoadjuvant therapy. (E-H) The enhanced-CT scans of the tumor after three cycles of neoadjuvant therapy.
fimmu-13-989966-g001.jpg
PMC9459224_01_fimmu-13-989966-g001.jpg
f1
The computed tomography (CT) scans showed that the malignant lesion, located between the left upper and lower lobes, had invaded the left pulmonary artery ( Figure 1 ).
(A, B) TEN and rash induced by sintilimab in the patient with advanced NSCLC. (C, D) An image of the skin after recovery from severe TEN.
fimmu-13-989966-g002.jpg
PMC9459224_01_fimmu-13-989966-g002.jpg
f2
The cutaneous lesions accounted for approximately 95% of the whole body surface ( Figure 2 ).
Anti-tuberculosis therapy: Isoniazid (300 mg per day), Rifampicin (450 mg per day), Ethambutol (750 mg per day), Pyrazinamide (1250 mg per day). Neoadjuvant therapy: Sintilimab (200 mg) plus platinum-based conventional chemotherapy (paclitaxel and cisplatin). PR, Partial response; TEN, Toxic epidermal necrolysis; AE, Adverse event.
fimmu-13-989966-g003.jpg
PMC9459224_01_fimmu-13-989966-g003.jpg
f3
TEN without any adverse events. The timeline of the treatment of the patient was presented in  Figure 3 .